Since CEACAM1 plays a crucial role in insulin resistance and in NAFLD development, we can hypothesize that pharmacologically upregulating CEACAM1 could be a promising therapeutic approach for the treatment of NAFLD in T1D. Here, CEACAM1 is linked to metabolic dysfunction-associated steatotic liver disease.